Search results for "Combination"

showing 10 items of 1379 documents

New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles

2013

Current B-cell disorder treatments take advantage of dose-intensive chemotherapy regimens and immunotherapy via use of monoclonal antibodies. Unfortunately, they may lead to insufficient tumor distribution of therapeutic agents, and often cause adverse effects on patients. In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. We demonstrate their ability to effectively target and internalize in tumor B-cells. Moreover, these nanoparticles were able to kill not only p53 mutated/deleted lymphoma cell lines expressing a low amount of CD20…

Lymphomamedicine.medical_treatmentlcsh:MedicineApoptosisnanoparticles; Targeting strategies; LymphomaAggressive lymphomaMice SCIDPharmacologyAntibodies Monoclonal Murine-DerivedMiceDrug Delivery Systems0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesNANOPARTICLESMedicinelcsh:ScienceCD200303 health sciencesMultidisciplinarybiologyNANOPARTICLES; ANTI-CD20; B-CELL MALIGNANCIESnanoparticleANTI-CD20Flow CytometryImmunohistochemistry3. Good healthDrug CombinationsLeukemia030220 oncology & carcinogenesisMonoclonalTargeting strategieFemaleRituximabRituximabHydroxychloroquineResearch Articlemedicine.drugLymphoma B-CellCell Survival03 medical and health sciencesMicroscopy Electron TransmissionAutophagyB-CELL MALIGNANCIESAnimalsTargeting strategies030304 developmental biologyChlorambucilbusiness.industrylcsh:RHydroxychloroquineImmunotherapyAntigens CD20medicine.diseaseDisease Models Animalbiology.proteinChlorambucillcsh:QbusinessPLoS ONE
researchProduct

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health

2011

William H. Chappell 1 , Linda S. Steelman 1,2 , Jacquelyn M. Long 2 , Ruth C. Kempf 2 , Stephen L. Abrams 1 , Richard A. Franklin 1 , Jorg Basecke 3 , Franca Stivala 4 , Marco Donia 4 , Paolo Fagone 4 , Graziella Malaponte 4 , Maria C. Mazzarino 4 , Ferdinando Nicoletti 4 , Massimo Libra 4 , Danijela Maksimovic-Ivanic 5 , Sanja Mijatovic 5 , Giuseppe Montalto 6 , Melchiorre Cervello 7 , Piotr Laidler 8 , Michele Milella 9 , Agostino Tafuri 10 , Antonio Bonati 11 , Camilla Evangelisti 12 , Lucio Cocco 12 , Alberto M. Martelli 12,13 , and James A. McCubrey 1 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University 2 Department of Physics, Greenville, N…

MAPK/ERK pathwayAgingmedicine.medical_treatmentDrug ResistancerafPI3KTargeted therapycombination therapyPhosphatidylinositol 3-Kinases0302 clinical medicineTARGETED THERAPYCANCER STEM CELLSNeoplasmsCancer Stem CellsMedicineExtracellular Signal-Regulated MAP Kinases0303 health sciencesCombination TherapybiologyTOR Serine-Threonine KinasesMTORHuman health Ras inhibitors MEK ERKTargeted TherapyDiscovery and development of mTOR inhibitors3. Good healthDRUG RESISTANCECell Transformation NeoplasticOncology030220 oncology & carcinogenesismTORraf KinasesPremature agingMAP Kinase Signaling SystemReviewsSenescence03 medical and health sciencesCell Line TumorHumansPTENProtein kinase BPI3K/AKT/mTOR pathway030304 developmental biologyMitogen-Activated Protein Kinase Kinasesbusiness.industryAKTAktagingPTEN PhosphohydrolaseRafTransplantationSENESCENCEImmunologyras Proteinsbiology.proteinCancer researchaging; akt; cancer stem cells; combination therapy; drug resistance; mtor; pi3k; raf; senescence; targeted therapybusinessProto-Oncogene Proteins c-akt
researchProduct

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition …

2007

The molecular mechanisms behind the anti-neoplastic effects of non-steroidal anti-inflammatory drugs (NSAIDs) are not completely understood and cannot be explained by the inhibition of the cyclooxygenase (COX) enzymes COX-1 and COX-2 alone. We previously reported that both the selective COX-1 inhibitor SC-560 and the selective COX-2 inhibitor CAY10404 exhibit anti-tumor effects in human hepatoma cells. NSAID inhibitors have many COX-independent actions and, among others, the mitogen-activated protein kinase (MAPK) pathways are targets for NSAIDs. Here, we examined the role of MEK/ERK1/2 signaling in the anti-neoplastic effects of both selective COX-1 and COX-2 inhibitors in two human hepato…

MAPK/ERK pathwayCancer ResearchCarcinoma HepatocellularTime FactorsBlotting WesternApoptosisPharmacologyCOX-1 COX-2 NSAIDs MEK1/2 ERK1/2NitrilesButadienesTumor Cells CulturedHumansCyclooxygenase InhibitorsSulfonesEnzyme InhibitorsPhosphorylationProtein kinase ACell ProliferationPharmacologychemistry.chemical_classificationMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase 3biologyDose-Response Relationship DrugLiver NeoplasmsCytochromes cLong-term potentiationDrug SynergismIsoxazolesFlow CytometryEnzymeOncologychemistryCyclooxygenase 2CaspasesCancer cellbiology.proteinCyclooxygenase 1Molecular MedicineMEK-ERK PathwayPyrazolesDrug Therapy CombinationCyclooxygenaseHepatoma cellCancer biologytherapy
researchProduct

Dental stem cell signaling pathway activation in response to hydraulic calcium silicate-based endodontic cements: A systematic review of in vitro stu…

2020

Abstract Objective To present a qualitative synthesis of in vitro studies which analyzed human dental stem cell (DSC) molecular signaling pathway activation in response to hydraulic calcium silicate-based cements (HCSCs). Methods A systematic electronic search was performed in Medline, Scopus, Embase, Web of Science and SciELO databases on January 20 and last updated on March 20, 2020. In vitro studies assessing the implication of signaling pathways in activity related marker (gene/protein) expression and mineralization induced by HCSCs in contact with human DSCs were included. Results The search identified 277 preliminary results. After discarding duplicates, and screening of titles, abstr…

MAPK/ERK pathwayMaterials scienceCellDental CementsBiocompatible Materials02 engineering and technologySMADBiological FactorsDental Materials03 medical and health sciences0302 clinical medicineCa2+/calmodulin-dependent protein kinaseMedicine and Health SciencesmedicineHumansdental stem cellsGeneral Materials ScienceGeneral DentistryBiomedical and Dental MaterialsFOS: Clinical medicineSilicatesStem CellsIn vitro toxicologyWnt signaling pathwayEndodontics and Endodontologycalcium silicate-based cementsin vitroOxides030206 dentistryCalcium Compoundsbiomineralization021001 nanoscience & nanotechnologysignaling pathwaysChemicals and DrugsCell biologyDrug Combinationsmedicine.anatomical_structurebioactivityMechanics of MaterialsDentistryStem cellSignal transduction0210 nano-technologySignal TransductionDental Materials
researchProduct

Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' fi…

2006

International audience; BACKGROUND: The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA. METHODS: A panel of 34 experts selected treatment option from various scenarios using the Thurstone pairwise method. The experts had to choose between two proposed DMARDs without proposing other options. The scenarios were obtained using the three items: DAS28, rheumatoid factor status and radiographic structural damage. A sample of 240 among 480 scenarios for each expert was taken at random. Responses given by at least 20% of the experts were considered per…

MESH: Antirheumatic AgentsMESH: Treatment FailureDiseaseReceptors Tumor Necrosis FactorEtanerceptArthritis Rheumatoid0302 clinical medicineMESH: Practice Guidelines as Topic030212 general & internal medicineTreatment Failureskin and connective tissue diseasesMESH: Immunoglobulin GMESH: Arthritis RheumatoidAnti rheumatic drugs3. Good healthClinical PracticeMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsPractice Guidelines as TopicDrug Therapy CombinationLeflunomidemusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorFirst lineMESH: Drug Administration ScheduleDrug Administration ScheduleDecision Support Techniques03 medical and health sciencesRheumatologyRheumatoid FactorDmard therapymedicineRheumatoid factorHumansIntensive care medicine030203 arthritis & rheumatologyMESH: HumansMESH: Sulfasalazinebusiness.industryMESH: Biological MarkersMESH: Decision Support TechniquesEarly rheumatoid arthritisIsoxazolesmedicine.diseaseMESH: Receptors Tumor Necrosis FactorRadiographySulfasalazineMESH: Drug Therapy CombinationMethotrexateMESH: IsoxazolesImmunoglobulin GPhysical therapybusinessBiomarkersJoint bone spine
researchProduct

Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.

2007

Ligand-activated Cre recombinases are widely used for studying gene function in vitro and in conditional mouse models. To compare ligand-dependent Cre recombinases, different Cre estrogen receptor fusions were introduced into the ROSA26 locus of embryonic stem (ES) cells and assayed for genotoxicity and recombination efficiency. Of the tested recombinases, the CreERT2 variant showed no toxicity and was highly responsive to ligand induction. To constitutively express CreERT2 in mice and also to clarify whether the CreERT2 system displays background activity, we generated a knock-in mouse line harboring the CreERT2 coding region under the control of the ROSA26 locus. Analysis of this ROSA26-…

MESH: IntegrasesPhysiologyMESH: Mice TransgenicTransgeneMice TransgenicMESH: Flow Cytometry[SDV.CAN]Life Sciences [q-bio]/CancerBiologyLigandsGreen fluorescent proteinMiceMESH: Brain[SDV.CAN] Life Sciences [q-bio]/CancerGenes ReporterGene expressionGeneticsRecombinaseMESH: LigandsAnimalsMESH: AnimalsMESH: Models GeneticGeneMESH: MiceRecombination GeneticIntegrasesModels GeneticMosaicismMESH: GenomicsMESH: Genes ReporterMESH: DNABrainDNAGenomicsFlow CytometryEmbryonic stem cellMolecular biologyPhenotypeDisease Models AnimalMESH: Gene DeletionMESH: Recombination GeneticMESH: MosaicismMESH: Disease Models AnimalFunctional genomicsGene Deletion
researchProduct

Evolutionary Dissection of the Dot/Icm System Based on Comparative Genomics of 58 Legionella Species

2019

14 páginas, 2 figuras, 2 tablas

MESH: Selection GeneticLegionella pneumophilaMESH: Bacterial Proteins/metabolism*Negative selectionPositive-selectionDot/Icm systemMESH: PhylogenyNegative-selectionPhylogenyMESH: Evolution MolecularRecombination Genetic0303 health sciencesEffectorMESH: GenomicsGenomics3. Good healthCell biologypositive-selectionDiversifying-selectionMESH: Recombination GeneticMESH: Membrane ProteinsResearch ArticleSignal peptidenegative-selectionEvolutionLegionellaMESH: Carrier ProteinsBiologyMESH: Bacterial Proteins/geneticsEvolution MolecularType IV Secretion Systems03 medical and health sciencesdiversifying-selectionMESH: Type IV Secretion Systems*Bacterial Proteins[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]evolutionGeneticsSecretionSelection GeneticEcology Evolution Behavior and SystematicsMESH: Legionella/classification030304 developmental biologyComparative genomicsMESH: Legionella/metabolism030306 microbiologyMESH: Legionella/geneticsMembrane ProteinsPeriplasmic spacebiology.organism_classificationCytoplasmCarrier Proteins
researchProduct

Mapping candidate genes for Drosophila melanogaster resistance to the parasitoid wasp Leptopilina boulardi.

2006

Drosophila melanogaster resistance against the parasitoid wasp Leptopilina boulardi is under the control of a single gene (Rlb), with two alleles, the resistant one being dominant. Using strains bearing deletions, we previously demonstrated that the 55E2–E6; 55F3 region on chromosome 2R is involved in the resistance phenomenon. In this paper, we first restricted the Rlb containing region by mapping at the molecular level the breakpoints of the Df(2R)Pc66, Df(2R)P34 and Df(2R)Pc4 deficiencies, using both chromosomal in situ hybridization and Southern analyses. The resistance gene was localized in a 100 kb fragment, predicted to contain about 10 different genes. Male recombination genetic exp…

Male0106 biological sciencesCandidate geneWaspsGenes Insect010603 evolutionary biology01 natural sciencesParasitoid wasp03 medical and health sciencesGenes RegulatorGeneticsAnimalsDrosophila Proteins[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyAlleleGeneIn Situ Hybridization030304 developmental biologyRecombination GeneticGenetics0303 health sciences[SDV.GEN]Life Sciences [q-bio]/GeneticsModels GeneticbiologyBreakpointIntracellular Signaling Peptides and ProteinsChromosome MappingMembrane ProteinsChromosomeGeneral MedicineCosmidsbiology.organism_classificationDrosophila melanogasterLarvaDrosophila melanogasterRecombination
researchProduct

Antischistosomal activity of artemisinin derivatives in vivo and in patients

2016

Schistosomiasis is a helminthic disease affecting more than 200 million people in the tropics as well as returning travellers. Treatment mainly relies on a single drug, praziquantel. Praziquantel cannot kill developing schistosomula resulting in frequent treatment failures and re-infections. Monotherapy also favors the selection for resistance. New drugs are therefore urgently needed. The activity of the semi-synthetic artemisinin derivatives artemether, artesunate and arteether is not restricted to malaria. We reviewed their anti-schistosomal activity in vivo and in patients by searching the PubMed database for publications since 1983 with the search terms "artemisinin" and "Schistosoma". …

Male0301 basic medicineCombination therapyArtesunateSchistosomiasisPharmacologySchistosomicides03 medical and health scienceschemistry.chemical_compoundparasitic diseasesmedicineAnimalsHumansSchistosomiasisArtemetherArtemisininParasite Egg CountSchistosomaPharmacologybiologymedicine.diseasebiology.organism_classificationArtemisininsPraziquantelTreatment Outcome030104 developmental biologychemistryArtesunateImmunologySchistosomaFemaleArtemetherMalariamedicine.drugPharmacological Research
researchProduct

Sexually Dimorphic Behavioral Profile in a Transgenic Model Enabling Targeted Recombination in Active Neurons in Response to Ketamine and (2R,6R)-Hyd…

2020

Background: Rapid-acting antidepressants ketamine and (2R,6R)-hydroxynorketamine ((2R,6R)-HNK) have overcome some of the major limitations of classical antidepressants. However, little is known about sex-specific differences in the behavioral and molecular effects of ketamine and (2R,6R)-HNK in rodents. Methods: We treated mice with an intraperitoneal injection of either saline, ketamine (30 mg kg&minus

Male0301 basic medicineHydroxynorketaminemedicine.medical_treatmentAntidepressantAnxietyHippocampuslcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5Salineactivated neuronsSpectroscopyNeuronsRecombination GeneticSex CharacteristicsBehavior AnimalhydroxynorketamineGeneral MedicineComputer Science ApplicationsActivated neuronsAntidepressantFemaleKetaminemedicine.drugmedicine.medical_specialtyketamineMemory Episodicsex differenceGreen Fluorescent ProteinsIntraperitoneal injectionMice TransgenicIn situ hybridizationBiologyHydroxynorketamineArticleCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineketamine ; sex difference ; activated neurons ; antidepressant ; behavior ; BDNF ; rapid-acting ; hydroxynorketaminemedicineAnimalsKetamineRapid-actingPhysical and Theoretical ChemistrySocial BehaviorMolecular BiologyCell NucleusBehaviorantidepressantbehaviorBrain-Derived Neurotrophic FactorOrganic ChemistrySex differencerapid-actingSexual dimorphismDisease Models AnimalBDNF030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999030217 neurology & neurosurgeryBehavioural despair test
researchProduct